Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa - PubMed (original) (raw)
Comparative Study
Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa
K D Awadelkarim et al. Histopathology. 2008 Mar.
Abstract
Aims: In patients of Black African ethnicity, breast cancer is reportedly characterized by aggressive, poorly differentiated phenotype(s). To highlight possible differences between breast cancer in indigenous sub-Saharan African and European patients, two breast cancer case series, from Central Sudan (Khartoum) and Northern Italy (Milan), were compared for clinicopathological characteristics, expression of oestrogen receptor (ER), progesterone receptor (PR), Her-2/neu, basal cytokeratin (CK) 5/6 and CK17, and breast cancer subtypes.
Methods and results: After careful antigen retrieval, 114 and 138 consecutive formalin-fixed paraffin-embedded (FFPE) breast cancer cases from the Radiation and Isotope Centre (Khartoum) and from MultiMedica (Milan), respectively, were screened by immunohistochemistry for ER, PR, Her-2/neu, CK5/6 and CK17. Compared with the Italian patients, the Sudanese patients were younger (P < 0.0001) and their tumours were larger (P < 0.0001), more advanced in stage (P < 0.00001), higher grade (P < 0.00001) and more frequently positive for nodal metastases (P < 0.00001). ER expression varied between the two series (P < 0.0008), but no significant differences were found for PR (P < 0.32), combined hormone receptors (P < 0.12), Her-2/neu (P < 0.09), CK5/6 (P < 0.1), CK17 (P = 0.4), combined basal CK status (P = 1) or breast cancer subtypes (P = 0.12).
Conclusion: The differences between the Sudanese and Italian breast cancer series reflect stage at diagnosis rather than intrinsic biological characteristics. This may have relevant implications for breast cancer prevention and treatment in Africa.
Similar articles
- Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
Sengal AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, Kantelhardt EJ, Mohamedani AA. Sengal AT, et al. BMC Cancer. 2017 Dec 1;17(1):804. doi: 10.1186/s12885-017-3805-4. BMC Cancer. 2017. PMID: 29191181 Free PMC article. - Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM. Fernandes RC, et al. Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x. Histopathology. 2009. PMID: 19723150 - Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN. Khabaz MN. Asian Pac J Cancer Prev. 2014;15(19):8395-400. doi: 10.7314/apjcp.2014.15.19.8395. Asian Pac J Cancer Prev. 2014. PMID: 25339035 - Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
Meattini I, Bicchierai G, Saieva C, De Benedetto D, Desideri I, Becherini C, Abdulcadir D, Vanzi E, Boeri C, Gabbrielli S, Lucci F, Sanchez L, Casella D, Bernini M, Orzalesi L, Vezzosi V, Greto D, Mangoni M, Bianchi S, Livi L, Nori J. Meattini I, et al. Eur J Surg Oncol. 2017 Apr;43(4):642-648. doi: 10.1016/j.ejso.2016.10.025. Epub 2016 Nov 17. Eur J Surg Oncol. 2017. PMID: 27889196 Review. - Response to treatment of breast cancer.
Berenberg JL. Berenberg JL. Breast Cancer Res Treat. 1991 May;18 Suppl 1:S147-55. doi: 10.1007/BF02633548. Breast Cancer Res Treat. 1991. PMID: 1651792 Review.
Cited by
- Immunohistochemical and Clinicopathological Characteristics of Invasive Breast Carcinoma in Nigeria.
Wemimo RM, Eziagu UB, Sulaiman OA, Abiodun AE, Idowu NA, Ayinde AA, Taiwo AA. Wemimo RM, et al. Oman Med J. 2023 Sep 28;38(5):e548. doi: 10.5001/omj.2023.101. eCollection 2023 Sep. Oman Med J. 2023. PMID: 38225996 Free PMC article. - Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia.
Belachew EB, Desta AF, Gebremariam TY, Deneke DB, Ashenafi S, Yeshi MM, Fenta BD, Alem AT, Alemu A, Abafogi AK, Desta T, Chanyalew M, Beshah D, Taylor L, Bauer M, Tsehay D, Girma S, Melka DS, Tessema TS, Kantelhardt EJ, Howe R. Belachew EB, et al. Front Endocrinol (Lausanne). 2023 Nov 9;14:1250189. doi: 10.3389/fendo.2023.1250189. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027092 Free PMC article. - Population-specific Mutation Patterns in Breast Tumors from African American, European American, and Kenyan Patients.
Tang W, Zhang F, Byun JS, Dorsey TH, Yfantis HG, Ajao A, Liu H, Pichardo MS, Pichardo CM, Harris AR, Yang XR, Figueroa JD, Sayed S, Makokha FW, Ambs S. Tang W, et al. Cancer Res Commun. 2023 Nov 7;3(11):2244-2255. doi: 10.1158/2767-9764.CRC-23-0165. Cancer Res Commun. 2023. PMID: 37902422 Free PMC article. - Pathologically confirmed women's breast cancer: A descriptive study of Tunisian and Algerian series.
Sassi F, Rekaya MB, Belarbi A, Chilla D, Mansouri N, Achouri L, Saied E, Kassa R, Kacem LB, Ouezani M, Debabeche N, Rebhi F, Rammeh S. Sassi F, et al. Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1818. doi: 10.1002/cnr2.1818. Epub 2023 Apr 24. Cancer Rep (Hoboken). 2023. PMID: 37092543 Free PMC article. - Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes.
Ding L, Greuter MJW, Truyen I, Goossens M, Van der Vegt B, De Schutter H, Van Hal G, de Bock GH. Ding L, et al. Cancers (Basel). 2022 Oct 3;14(19):4831. doi: 10.3390/cancers14194831. Cancers (Basel). 2022. PMID: 36230754 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous